GENE ONLINE|News &
Precision Oncology in Focus at ESMO 2025: New Data Across Rare Cancers, CML, and Solid Tumors
From HER2-positive colorectal cancer to neuroendocrine tumors, CML, and mesothelioma—ESMO 2025 spotlights data-driven therapies reshaping precision oncology across rare and solid cancers. Image: iStock
The European Society for Medical Oncology (ESMO) Congress has become a bellwether for where global cancer research is heading — not just in new drugs, but in how data, biology, and technology intersect to redefine treatment. At this year’s meeting, several studies stand out for showing how the next decade of oncology will be built: … Precision Oncology in Focus at ESMO 2025: New Data Across Rare Cancers, CML, and Solid Tumors Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.
GO Prime with only $1.49 now
LATEST
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
